1
|
Morelli A, Bungaro M, Capizzi I, Parlagreco E, Solitro F, Eletti L, Martinetto S, Veltri A, Tinivella M, Pedrazzoli P, Caccialanza R, Bertaglia V, Capelletto E, Reale M, Novello S, Tampellini M. 1617P Impact of nutritional counselling (NC) on CT-based body composition in patients with oncogene addicted advanced non-small cell lung cancer (aNSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Morelli A, Capizzi I, Bungaro M, Solitro F, Eletti L, Martinetto S, Veltri A, Tinivella M, Pedrazzoli P, Caccialanza R, Bertaglia V, Capelletto E, Reale M, Tampellini M, Novello S. EP10.01-015 The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Capizzi I, Morelli A, Carnio S, Paratore C, Bungaro M, Alemanni A, Tinivella M, Tiozzo E, Pedrazzoli P, Caccialanza R, Bertaglia V, Capelletto E, Reale M, Tampellini M, Novello S. Prognostic nutritional index (pni) in oncogene addicted advanced non-small cell lung cancer (ansclc) patients (pts): an Italian experience. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V, Amatu A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Corallo S, Morano F, Di Bartolomeo M, Di Maio M, Pietrantonio F. Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ESMO Open 2021; 6:100246. [PMID: 34416469 PMCID: PMC8379288 DOI: 10.1016/j.esmoop.2021.100246] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 07/23/2021] [Accepted: 07/28/2021] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND The safety and efficacy outcome of elderly metastatic colorectal cancer (mCRC) patients fit enough to receive combination chemotherapy plus biological agents is an issue of growing interest. Also, gender-specific differential toxicity and efficacy of anti-epidermal growth factor receptor (EGFR)-based upfront treatments need to be explored. PATIENTS AND METHODS Valentino was a multicenter, randomized, phase II trial, investigating two panitumumab-based maintenance strategies following first-line panitumumab plus FOLFOX in RAS wild-type mCRC patients. We carried out a subgroup analysis, aimed at assessing the differences in efficacy, safety and quality of life (QoL) according to age (<70 versus ≥70 years) and gender (male versus female). Efficacy endpoints were progression-free survival (PFS), overall survival (OS) and overall response rate (ORR); safety endpoints were rates of any grade and grade 3/4 adverse events (AEs). RESULTS No significant differences in terms of PFS, OS and ORR were observed between patients aged <70 or ≥70 years and the effect of the maintenance treatment arm on survival outcomes was similar in the two subgroups. The safety profile of both induction and maintenance treatment and the impact on QoL were similar in elderly and younger patients. No significant differences in PFS, OS, ORR or clinical benefit rate were observed according to gender. A significantly higher rate of overall grade 3/4 AEs (P = 0.008) and of grade 3/4 thrombocytopenia (P = 0.017), any grade and grade 3/4 neutropenia (P < 0.0001) and any grade conjunctivitis (P = 0.033) was reported in female as compared to male patients. Conversely, we reported a significantly higher incidence of any grade skin rash (P = 0.0007) and hypomagnesemia (P = 0.029) in male patients. CONCLUSIONS The upfront choice of an anti-EGFR-based doublet chemotherapy followed by a maintenance strategy represents a valuable option in RAS wild-type mCRC irrespective of gender and age, though a careful evaluation of patients to maximize the risk/benefit ratio is warranted.
Collapse
Affiliation(s)
- A Raimondi
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Fucà
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A G Leone
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Lonardi
- Medical Oncology Unit 3, Department of Oncology, Istituto Oncologico Veneto-IRCCS, Padua, Italy
| | - C Antoniotti
- Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - V Smiroldo
- Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - A Amatu
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - M Tampellini
- Department of Oncology, AOU San Luigi di Orbassano, University of Torino, Orbassano, Italy
| | - G Ritorto
- SSD ColoRectal Cancer Unit, Oncology Department, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy
| | - R Murialdo
- Department of Internal Medicine, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy
| | - M Clavarezza
- Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy
| | - A Zaniboni
- Medical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy
| | - R Berenato
- Medical Oncology Unit, A.O. Papardo, Messina, Italy
| | - M Ratti
- Medical Oncology Unit, ASST Ospedale di Cremona, Cremona, Italy
| | - S Corallo
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F Morano
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Di Bartolomeo
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Di Maio
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Torino, Italy
| | - F Pietrantonio
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|
5
|
Raimondi A, Di Maio M, Peverelli G, Morano F, Corallo S, Bergamo F, Cremolini C, Smiroldo V, Amatu A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Noventa S, Adamo V, Ratti M, Petrelli F, Antonuzzo L, Palermo M, de Braud F, Di Bartolomeo M, Pietrantonio F. Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Morano F, Corallo S, Di Bartolomeo M, Lonardi S, Cremolini C, Rimassa L, Sartore Bianchi A, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Tampellini M, Fanchini L, Schirripa M, Clavarezza M, Petrelli F, Longarini R, Cinieri S, de Braud F, Pietrantonio F. Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Pietrantonio F, Morano F, Corallo S, Raimondi A, Loupakis F, Cremolini C, Smiroldo V, Berenato R, Bianchi AS, Tampellini M, Bustreo S, Clavarezza M, Murialdo R, Zaniboni A, Tomasello G, Peverelli G, Antoniotti C, Procaccio L, Cinieri S, Antonuzzo L, Di Bartolomeo M, de Braud F. First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol 2018; 28:3009-3014. [PMID: 29045518 DOI: 10.1093/annonc/mdx546] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background Refining the selection of metastatic colorectal cancer patients candidates for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies beyond RAS and BRAF testing is a challenge of precision oncology. Several uncommon genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than EGFR or downstream signalling pathways, have been suggested by preclinical and retrospective studies. Patients and methods We conducted this multicentre, prospective, case-control study to demonstrate the negative predictive impact of a panel of rare genomic alterations [PRESSING (PRimary rESiStance IN RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-eGfr monoclonal antibodies) panel], including HER2/MET amplifications, ALK/ROS1/NTRK1-3/RET fusions and PIK3CA mutations. Hypothesizing a prevalence of candidate alterations of 15% and 0% in resistant and sensitive RAS and BRAF wild-type patients, respectively, with two-sided α and β errors of 0.05 and 0.20, 47 patients per group were needed. Results Forty-seven patients per group were included. PRESSING panel alterations were significantly more frequent in resistant (24 out of 47, 51.1%) than in sensitive (1 out of 47, 2.1%) patients (P < 0.001) and in right- (12 out of 29, 41.4%) than left-sided (13 out of 65, 20.0%) tumours (P = 0.03). The predictive accuracy of PRESSING panel and sidedness was 75.3% and 70.2%, respectively. Among hyper-selected patients, right-sidedness was still associated with resistance (P = 0.002). The predictive accuracy of the combined evaluation of PRESSING panel and sidedness was 80.4%. As a secondary analysis, 8 (17.0%) resistant and 0 sensitive patients showed microsatellite instability (P < 0.001). Conclusion The investigated panel of genomic alterations allows refining the selection of RAS and BRAF wild-type metastatic colorectal cancer patients candidates for anti-EGFRs, partially explaining and further corroborating the predictive ability of primary tumour sidedness.
Collapse
Affiliation(s)
- C Cremolini
- Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa
| | - F Morano
- Medical Oncology Department, IRCCS Istituto Nazionale dei Tumori, Milan
| | - R Moretto
- Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa
| | - R Berenato
- Medical Oncology Department, IRCCS Istituto Nazionale dei Tumori, Milan
| | - E Tamborini
- Laboratory of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - F Perrone
- Laboratory of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - D Rossini
- Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa
| | - A Gloghini
- Laboratory of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - A Busico
- Laboratory of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - G Zucchelli
- Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa
| | - C Baratelli
- Department of Oncology, University of Turin - Ordine Mauriziano Hospital, Turin
| | - E Tamburini
- Department of Oncology, Ospedale Infermi, Rimini
| | - M Tampellini
- Department of Oncology, Ospedale San Luigi, Orbassano
| | - E Sensi
- Department of Surgical, Medical, Molecular Pathology and Critical Care, Università di Pisa, Pisa
| | - G Fucà
- Medical Oncology Department, IRCCS Istituto Nazionale dei Tumori, Milan
| | - C Volpi
- Laboratory of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - M Milione
- Laboratory of Experimental Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - M Di Maio
- Department of Oncology, University of Turin - Ordine Mauriziano Hospital, Turin
| | - G Fontanini
- Department of Surgical, Medical, Molecular Pathology and Critical Care, Università di Pisa, Pisa
| | - F De Braud
- Medical Oncology Department, IRCCS Istituto Nazionale dei Tumori, Milan.,Department of Oncology and Hematoncology, University Of Milan, Milan, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy
| | - A Falcone
- Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa
| | - F Pietrantonio
- Medical Oncology Department, IRCCS Istituto Nazionale dei Tumori, Milan
| |
Collapse
|
9
|
Berruti A, Gorzegno G, Vitetta G, Tampellini M, Dogliotti L. Hypertriglyceridemia during Long-Term Interferon-Alpha Therapy: Efficacy of Diet and Gemfibrosil Treatment. A Case Report. Tumori 2018; 78:353-5. [PMID: 1494811 DOI: 10.1177/030089169207800515] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Interferon-alpha might increase triglyceride serum levels through the enhancement of hepatic lipogenesis and/or inhibition of the peripheral lipoprotein lipase. Hypertriglyceridemia during interferon-alpha therapy has been only recently described, mostly in patients with previous abnormalities of lipid metabolism. The authors report here a case of a 65-year-old male bearing advanced colon carcinoma who developed hypertriglyceridemia during long-term interferon-alpha treatment in association with 5 fluorouracil administration. Hypertriglyceridemia was maintained within acceptable levels, without adjusting the treatment plan, by an appropriate diet and gemfibrosil administration.
Collapse
Affiliation(s)
- A Berruti
- Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Ospedale S. Luigi Gonzaga, Orbassano, Italy
| | | | | | | | | |
Collapse
|
10
|
Brizzi MP, La Salvia A, Tampellini M, Sonetto C, Volante M, Scagliotti GV. Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review. BMC Cancer 2018; 18:311. [PMID: 29558899 PMCID: PMC5861646 DOI: 10.1186/s12885-018-4205-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 03/09/2018] [Indexed: 12/03/2022] Open
Abstract
Background Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established. Case presentation We describe the case of a 47-year-old man with end-stage renal disease who received everolimus plus Lanreotide for 9 months for the management of metastatic atypical bronchial carcinoid. Conclusions Everolimus is a treatment option for hemodialysis patients with metastatic atypical bronchial carcinoid. Based on our case report and review of literature, Everolimus does not require any dose reductions and is overall well tolerated in hemodialysis patients.
Collapse
Affiliation(s)
- M P Brizzi
- Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy.
| | - A La Salvia
- Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy
| | - M Tampellini
- Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy
| | - C Sonetto
- Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy
| | - M Volante
- Department of Medical Oncology and Pathology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy
| | - G V Scagliotti
- Medical Oncology, Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi, Regione Gonzole 10, 10043, Orbassano, Turin, Italy
| |
Collapse
|
11
|
Racca S, Conti G, Pietribiasi F, Stramignoni D, Tampellini M, Valetto MR, Ghezzo F, Di Carlo F. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Int J Biol Markers 2018; 10:87-93. [PMID: 7561244 DOI: 10.1177/172460089501000204] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The cytosolic levels of pS2, an estrogen-regulated protein, were measured in 100 cases of primary breast cancer and related to several conventional histological and biochemical prognostic factors. The data were statistically analyzed on the basis of two different cutoff points for pS2: 4 and 11 ng/mg of cytosolic proteins. pS2 positivity (cutoff 11 ng/mg) was shown to be associated with smaller tumor size (p = 0.05), a higher differentiation grade (p = 0.007) and a smaller number of mitoses (p = 0.004), but not with menopausal status, lymph node involvement, cathepsin D levels, or proliferative activity determined by the monoclonal antibody Ki67. With the cutoff of 4 ng/mg, the statistical significance was confirmed only for the number of mitoses (p = 0.03), which was also the most closely related covariate in multivariate analysis (p = 0.008). As regards steroid receptor status, a significant difference was observed between pS2+ and pS2– cases (Chi-square = 8.9; p - 0.04, cutoff 4 ng/mg). In conclusion, pS2 positivity, being preferentially expressed in hormone-dependent cells and related to other well-known positive markers, may either indicate a good prognosis or predict responsiveness to endocrine treatment.
Collapse
Affiliation(s)
- S Racca
- Dipartimento di Scienze Cliniche e Biologiche, Facoltà di Medicina, Orbassano, Torino, Italy
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Guercio S, Torta M, Tampellini M, Dovio A, Poggio M, Scarpa R, Angeli A. Metabolic Effects of Single-Dose Pamidronate Administration in Prostate Cancer Patients with Bone Metastases. Int J Biol Markers 2018. [DOI: 10.1177/172460080201700405] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Increased osteolysis usually accompanies sclerotic bone metastases from prostate cancer. This provides a rationale for the use of bisphosphonates to treat bone pain and prevent skeletal complications. Methods The fasting urinary levels of calcium, hydroxyproline (OHPRO), pyridinolines (PYD), deoxypyridinolines (DPYD), collagen cross-linked N-telopeptide (NTX) and the serum values of calcium, total alkaline phosphatase and relevant bone isoenzyme, bone gla protein (BGP), carboxy-telopeptide of type I collagen (ICTP) and parathyroid hormone (PTH) were determined at baseline and on the 15th, 30th, 60th and 90th days after single-dose (90 mg) pamidronate administration in 35 consecutive prostate cancer patients with bone metastases. These biochemical indices and serum interleukin 6 (IL-6) were also measured after four days in the last consecutive 17 cases. Results PYD, DPYD and NTX showed a significant decrease lasting four weeks (p<0.01, <0.01 and <0.001, respectively). OHPRO and ICTP did not change significantly. The NTX decline was greater than that of PYD and DPYD (maximum percent decrease: −71.3, −23.1 and −28.2, respectively). Bone formation markers and serum calcium did not change significantly. Serum PTH showed a rapid initial increase followed by a slow decrease (p<0.001). DPYD and NTX patterns did not correlate with changes in bone pain. As observed in the last 17 cases, the maximum osteolysis inhibition after pamidronate occurred on the fourth day after drug infusion. Serum IL-6 levels showed a short-lived decrease preceded by a transient rise on the fourth day. Conclusions Pamidronate is able to induce a decrease in bone resorption without significantly influencing bone formation. The maximum decrease in bone resorption occurs very early. NTX is the most sensitive bone resorption marker in bisphosphonate therapy monitoring. Changes in IL-6 but not bone resorption markers may be useful in the prediction of symptomatic response.
Collapse
Affiliation(s)
- A. Berruti
- Department of Medical Oncology University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - L. Dogliotti
- Department of Medical Oncology University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - M. Tucci
- Department of Medical Oncology University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - R. Tarabuzzi
- Department of Urology, University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - S. Guercio
- Department of Urology, University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - M. Torta
- Department of Medical Oncology University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - M. Tampellini
- Department of Medical Oncology University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - A. Dovio
- Department of Internal Medicine University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - M. Poggio
- Department of Urology, University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - R.M. Scarpa
- Department of Urology, University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| | - A. Angeli
- Department of Internal Medicine University of Torino, San Luigi Hospital, Orbassano (TO) - Italy
| |
Collapse
|
13
|
Tampellini M, Falco E, De Rosa G, Montarolo F, Dacomo R, Baratelli C, Sperti E, Di Maio M, Scagliotti G, Volante M. Correlation of PD-L1 staining between primitive tumor and metastasis in advanced colorectal cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Abstract
INTRODUCTION Cholangiocarcinoma (CCA) is an epithelial cell malignancy arising from bile ducts and/or peribiliary glands. Even though it is considered as a rare neoplasm, its incidence is raising, particularly in developed countries. Prognosis is generally poor with few patients who present the inclusion criteria for surgery (the mainstay treatment for this tumour). Several genetic alterations potentially driving tumour progression have been described, representing a possible target for new compounds. Areas covered: A clinical trial search in Clinicaltrials.gov encompassing a literature search in PubMed and ASCO/ESMO Websites was undertaken in March 2016. Expert opinion: Notwithstanding a large number of drug tested, results are still disappointing. The main reasons could be the low number of patients enrolled in trials, and the lack of a patient selection based on the biological profile of the tumours. Potential active drugs could have been discharged simply because beneficial in a particular subgroup of patients and not in un unselected population. The future direction of the research should consider biomarker evaluation in order to describe the genetic alteration/s that drive tumour progression and aggressiveness and the mechanisms of drug resistance. Finally, it will be of great interest to consider the results of immunotherapy whenever available.
Collapse
Affiliation(s)
- M Tampellini
- a Department of Oncology, AOU San Luigi di Orbassano , University of Turin , Torino , Italy
| | - A La Salvia
- a Department of Oncology, AOU San Luigi di Orbassano , University of Turin , Torino , Italy
| | - G V Scagliotti
- a Department of Oncology, AOU San Luigi di Orbassano , University of Turin , Torino , Italy
| |
Collapse
|
15
|
Sonetto C, Baratelli C, Brizzi M, Di Maio M, Scagliotti G, Tampellini M. Pharmacological bioquivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Sonetto C, Baratelli C, Brizzi M, Di Maio M, Scagliotti G, Tampellini M. Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Tampellini M, La Salvia A, Baratelli C, Di Scipio F, Pirro E, Brizzi M, Sonetto C, Di Maio M, Berta G, Scagliotti G. Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Brizzi M, Baratelli C, Di Maio M, Sonetto C, Bironzo P, La Salvia A, Scagliotti G, Tampellini M. Treatment of patients with metastatic colorectal cancer in a real-word scenario: probability of being submitted and clinical benefit of second and further lines of therapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Chiara B, Zichi C, Di Maio M, Sonetto C, Brizzi M, Scagliotti G, Tampellini M. A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Baratelli C, Sonetto C, Benedetto S, Rubatto E, Di Scipio F, Pirro E, Brizzi Maria P, Di Maio M, Berta Giovanni N, Scagliotti Giorgio V, Tampellini M. P-202 Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Abstract
INTRODUCTION Anti-angiogenetic agents are currently the standard of care in metastatic CRC patients. Bevacizumab, aflibercept, regorafenib and recently ramucirumab have significantly improved both progression-free and overall survival in different lines of treatment. Since bevacizumab's approval, a number of novel anti-VEGF agents have been tested in preclinical and clinical models. AREAS COVERED This review is focused on the most recent clinical results of novel agents targeting VEGF and its receptors with a major focus on those investigated recently in clinical trials. EXPERT OPINION In the last 15 years, a number of new anti-angiogenetic agents have been tested. Unfortunately, most of them have demonstrated unacceptable toxicities or failed to show activity. When tested as single agents, encouraging preliminary results were reported with fruquintinib, famitinib, and nintedanib. Interesting novel mechanisms of action are also being explored: VGX-100 is a monoclonal antibody (mAb) which binds to VEGF-C, inhibiting activation of VEGFR-2 and VEGFR-3 when combined with bevacizumab; tanibirumab is a mAb which binds to VEGFR-2 and vanucizumab is a bispecific mAb binding both to VEGF-A and Angiopoietin-2. Data about the combination of these agents with chemotherapy are very encouraging, even though preliminary. However, the definition of specific predictive biomarkers remains a priority.
Collapse
Affiliation(s)
- M Tampellini
- a University of Turin , Department of Oncology, AOU San Luigi di Orbassano , Torino , Italy
| | - C Sonetto
- a University of Turin , Department of Oncology, AOU San Luigi di Orbassano , Torino , Italy
| | - G V Scagliotti
- a University of Turin , Department of Oncology, AOU San Luigi di Orbassano , Torino , Italy
| |
Collapse
|
22
|
Tampellini M, Polverari RS, Ottone A, Alabiso I, Baratelli C, Bitossi R, Brizzi MP, Leone F, Forti L, Bertona E, Racca P, Mecca C, Alabiso O, Aglietta M, Berruti A, Scagliotti GV. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Chronobiol Int 2015; 32:1359-66. [PMID: 26540634 DOI: 10.3109/07420528.2015.1093495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Seasonal variation of baseline diagnosis (or clinical suspect) of stage I-III colorectal cancer patients has been repeatedly reported as an independent variable influencing overall survival. However, data are conflicting and no information is available about such a rhythm in advanced stage patients. To test whether a circannual rhythm of efficacy outcomes can be detected in this setting, we collected data about response rate (RR), progression-free survival (PFS), and overall survival (OS) to first-line chemotherapy of 1610 newly diagnosed metastatic patients treated at four independent centers. Responses to first-line chemotherapy were available for 1495 patients. A strong circannual rhythm in RR was evident, with the higher proportion of responding patients in the subgroup diagnosed in January (acrophase). At the time of data cutoff, 1322 patients progressed and 986 died, with median PFS and OS of 11 and 25.6 months, respectively. A circannual rhythmicity of the proportion of patients progressing at 6 months and surviving at 1 year was demonstrated, with acrophases located both in winter (February and January, respectively), similar to what reported for RR. Several interpretations about the genesis of this cyclic variation could be claimed: the rhythm in sunlight exposure and, as a consequence, of vitamin D serum levels and folate degradation, the variability in toxic effect intensity of chemotherapy, and the rhythm in the biological behavior of tumor cells. This observation is worth of further investigation both in preclinical and in clinical settings in order to better elucidate the underlying mechanisms.
Collapse
Affiliation(s)
- M Tampellini
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - R S Polverari
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - A Ottone
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - I Alabiso
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - C Baratelli
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - R Bitossi
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - M P Brizzi
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| | - F Leone
- c Division of Medical Oncology at IRCCS Candiolo , Candiolo , Italy
| | - L Forti
- d Division of Medical Oncology , University of Oriental Piedmont , Novara , Italy , and
| | - E Bertona
- d Division of Medical Oncology , University of Oriental Piedmont , Novara , Italy , and
| | - P Racca
- e ColoRectal Cancer Unit , Oncologia 1, AOU Città della Salute , Torino
| | - C Mecca
- e ColoRectal Cancer Unit , Oncologia 1, AOU Città della Salute , Torino
| | - O Alabiso
- d Division of Medical Oncology , University of Oriental Piedmont , Novara , Italy , and
| | - M Aglietta
- c Division of Medical Oncology at IRCCS Candiolo , Candiolo , Italy
| | - A Berruti
- b Department of Medical and Surgical Specialties , Radiological Sciences and Public Health, Division of Medical Oncology, University of Brescia , Brescia , Italy
| | - G V Scagliotti
- a Department of Oncology , Division of Medical Oncology, San Luigi Hospital, University of Torino , Torino , Italy
| |
Collapse
|
23
|
Tampellini M, Ottone A, Alabiso I, Baratelli C, Bitossi R, Brizzi M, Leone F, Forti L, Bertona E, Racca P, Mecca C, Alabiso O, Aglietta M, Berruti A, Scagliotti G. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Tampellini M, Ottone A, Alabiso I, Baratelli C, Forti L, Berruti A, Aroasio E, Scagliotti GV. The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumour Biol 2014; 36:1519-27. [PMID: 25374062 DOI: 10.1007/s13277-014-2693-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 09/30/2014] [Indexed: 10/24/2022] Open
Abstract
Serum marker evaluation is an easily available prognostic indicator that may help clinicians to discriminate patients with an aggressive disease; there are few and small-sized studies exploring the prognostic role of baseline carcinoembryonic antigen (CEA) values and their variations during first-line therapy, and even fewer data are available for carbohydrate antigen 19-9 (CA 19-9). Our aim was to analyze the role of those prognostic markers to exploit them in daily clinical practice. Data of 892 patients with marker determination before and 3 and/or 6 months during therapy were extracted from two institutional databases. Patients were grouped according to single marker variation as always negative (G0), decreasing (G1), stable (G2), or increasing (G3). We evaluated the progression-free survival (PFS) and the overall survival (OS) of all the patents and correlated them with CEA and CA 19-9 values. A concordance between response to therapy and marker decrease was evident in 50.2% and in 34.4% of the patients for CEA and CA 19-9. Patients with low CEA or CA 19-9 baseline values had a longer PFS (15.1 vs. 10.5; 13.6 vs. 10.2 months) and OS (32.0 vs. 22.3; 30.5 vs. 20.1 months). The same results of PFS and OS were obtained by analyzing the data of the four different groups. Multivariate analyses confirmed the independent prognostic role of CEA and CA 19-9. Baseline CEA and CA 19-9 levels and their kinetics demonstrated to be independent prognostic factors. CA 19-9 dosage is not recommended; a possible role of CA 19-9 in patients with negative CEA could be worth further evaluation.
Collapse
Affiliation(s)
- M Tampellini
- SCDU Oncologia, AOU San Luigi Gonzaga, Orbassano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Tampellini M, Alabiso I, Sculli CM, Barberis M, Giachino D, Berruti A, Dogliotti L. Stage IB Malignant Thymoma in a Lynch Syndrome Patient with Multiple Cancers: Response to Incidental Administration of Oxaliplatin and 5-Fluorouracil. J Chemother 2013; 18:433-6. [PMID: 17024802 DOI: 10.1179/joc.2006.18.4.433] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Chemotherapy is active against malignant thymomas, improving the resectability rate and the outcome of the advanced stages. The CAP and ADOC schemes are considered the standard schedules today, but these regimens can have important side effects in patients treated with combined approaches, such as toxic deaths due to congestive heart failure or hepatic insufficiency. We report the case of a 55 year-old woman with a history of multiple neoplasms including a mixed malignant thymoma WHO type B2 and three synchronous adenocarcinomas of the colon. The patient refused to undergo surgical resection of her mediastinal mass. However, 8 cycles of chronomodulated oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment for her colon cancers resulted in a > 30% decrease in the longest diameter of the mediastinal mass. This occasional observation may be important for clinicians and especially for those faced with relapsed, cisplatin-refractory disease or when planning new studies aiming to reduce overall toxicity of multimodal schedules.
Collapse
Affiliation(s)
- M Tampellini
- Department of Medical Oncology, University of Turin, San Luigi Hospital, Regione Gonzole 10, Orbassano, Italy
| | | | | | | | | | | | | |
Collapse
|
26
|
Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol 2012; 23:3110-3116. [PMID: 22745214 DOI: 10.1093/annonc/mds148] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Molecular circadian clocks can modify cancer chemotherapy effects, with a possible moderation according to sex differences. We investigated whether sex determine the optimal delivery schedule of chemotherapy for metastatic colorectal cancer. PATIENTS AND METHODS A meta-analysis was performed using individual data from three international Phase III trials comparing 5-fluorouracil, leucovorin and oxaliplatin administered in chronomodulated (chronoFLO) or conventional (CONV) infusions. The data from 345 females and 497 males were updated at 9 years. The main end point was survival. RESULTS Overall survival was improved in males on chronoFLO when compared with CONV (P = 0.009), with respective median values of 20.8 (95% CL, 18.7 to 22.9) and 17.5 months (16.1 to 18.8). Conversely, median survival was 16.6 months (13.9 to 19.3) on chronoFLO and 18.4 months (16.6 to 20.2) on CONV in females (P = 0.012). The sex versus schedule interaction was a strong predictive factor of optimal treatment schedule, with a hazard ratio of 1.59 (1.30 to 1.75) for overall survival (P = 0.002) in multivariate analysis. CONCLUSIONS Males lived significantly longer on chronomodulated chemotherapy rather than on conventional chemotherapy. The current chronoFLO schedule deserves prospective assessment as a safe and more effective first-line treatment option than conventional delivery for male patients.
Collapse
Affiliation(s)
- S Giacchetti
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France
| | - P A Dugué
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France
| | - P F Innominato
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France
| | - G A Bjarnason
- Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada
| | - C Focan
- Department of Medical Oncology, Centre Hospitalier Chrétien, Clinique Saint-Joseph, Liège, Belgium
| | - C Garufi
- Department of Medical Oncology C, Istituto Regina Elena, Roma
| | - S Tumolo
- Department of Medical Oncology, Azienda Ospedaliera Santa Maria Degli Angeli, Pordenone, Italy
| | - B Coudert
- Department of Medical Oncology, Georges-François Leclerc Center, Dijon, France
| | - S Iacobelli
- Department of Medical Oncology, G. D'Annunzio di Chieti University, Chieti, Italy
| | - R Smaaland
- Department of Hematology and Oncology, Stavanger University Hospital, Stavanger; University of Bergen, Norway
| | - M Tampellini
- Department of Medical and Biological Sciences, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Torino, Italy
| | - R Adam
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France; Onco-surgery Unit, Hepato-biliary Center, France
| | - T Moreau
- Department of Biostatistics, INSERM U1018, Paul Brousse Hospital, Villejuif, France
| | - F Lévi
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France.
| |
Collapse
|
27
|
Leone F, Marino D, Artale S, Cagnazzo C, Cascinu S, Martoni A, Sobrero A, Tampellini M, Siena S, Aglietta M. Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33219-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
28
|
Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 2012; 23:2072-2077. [PMID: 22219016 DOI: 10.1093/annonc/mdr572] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. PATIENTS AND METHODS This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. RESULTS Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P=0.009) and produced a trend toward improved overall survival versus no zoledronic acid. CONCLUSION This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.
Collapse
Affiliation(s)
- D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome.
| | - M Tampellini
- Department of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano, Torino
| | - B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - T Ibrahim
- Osteo-oncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì-Cesena
| | - C Ortega
- Oncological Department, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino
| | - V Virzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - N Silvestris
- Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari
| | - R Berardi
- Department of Medical Oncology, Universita Politecnica delle Marche, Ancona
| | - C Masini
- Department of Medical Oncology, University Hospital, Modena
| | - N Calipari
- Department of Radiotherapy, Ospedali Riuniti, Reggio Calabria
| | - D Ottaviani
- Department of Medical Oncology, Presidio Sanitario Gradenigo, Turin
| | - V Catalano
- Department of Medical Oncology, A.O. Ospedali Riuniti Marche Nord, Pesaro
| | - G Badalamenti
- Department of Surgery and Oncology, Policlinico Universitario 'P. Giaccone', Palermo
| | - R Giannicola
- Department of Medical Oncology, Ospedali Riuniti, Reggio Calabria
| | - F Fabbri
- Osteo-oncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì-Cesena
| | - O Venditti
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - M E Fratto
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - C Mazzara
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - T P Latiano
- Department of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
| | - F Bertolini
- Department of Medical Oncology, University Hospital, Modena
| | - F Petrelli
- Department of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Bergamo
| | - A Ottone
- Department of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano, Torino
| | - C Caroti
- S.C. Medical Oncology, Galliera Hospital, Genoa
| | - L Salvatore
- Division of Medical Oncology, Department of Oncology, University Hospital S. Chiara, Pisa
| | - A Falcone
- Division of Medical Oncology, Department of Oncology, University Hospital S. Chiara, Pisa
| | - P Giordani
- Department of Medical Oncology, A.O. Ospedali Riuniti Marche Nord, Pesaro
| | - R Addeo
- Department of Medical Oncology, Ospedale San Giovanni di Dio di Frattamaggiore, Naples
| | - M Aglietta
- Oncological Department, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino; Department of Clinical Oncology, University of Torino Medical School - Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
| | - S Cascinu
- Department of Medical Oncology, Universita Politecnica delle Marche, Ancona
| | - S Barni
- Department of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Bergamo
| | - E Maiello
- Department of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| |
Collapse
|
29
|
Saini A, Tucci M, Tampellini M, Maina D, Bouraouia K, Giuliano P, Termine A, Castellano M, Campagna S, Laciura P, Berruti A. Circadian variation of breakthrough pain in cancer patients. Eur J Pain 2012; 17:264-70. [DOI: 10.1002/j.1532-2149.2012.00184.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2012] [Indexed: 11/12/2022]
Affiliation(s)
- A. Saini
- Medical Oncology; Department of Clinical and Biological Sciences; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - M. Tucci
- Medical Oncology; Department of Clinical and Biological Sciences; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - M. Tampellini
- Medical Oncology; Department of Clinical and Biological Sciences; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - D. Maina
- Nurse Teaching Unit; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - K. Bouraouia
- Nurse Teaching Unit; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - P.L. Giuliano
- Medical Oncology; Department of Clinical and Biological Sciences; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - A. Termine
- Laboratory of Internal Medicine; Department of Clinical and Biological Sciences; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - M. Castellano
- Pain Management Center; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - S. Campagna
- Nurse Teaching Unit; San Luigi Gonzaga Hospital; Orbassano; Italy
| | - P. Laciura
- Palliative Care Unit; Hospice; Local Health District Cuneo 1; Busca; Italy
| | - A. Berruti
- Medical Oncology; Department of Clinical and Biological Sciences; San Luigi Gonzaga Hospital; Orbassano; Italy
| |
Collapse
|
30
|
Saini A, Tucci M, Bouraouia K, Ghio P, Tampellini M, Furlan PM, Ostacoli L, Dogliotti L, Berruti A. Circadian rhythm of breakthrough cancer pain. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Bellini E, Pia A, Brizzi M, Tampellini M, Torta M, Terzolo M, Dogliotti L, Berruti A. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011; 22:988-990. [DOI: 10.1093/annonc/mdr010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Vignani F, Russo L, Tucci M, Motta M, Vellani G, Tampellini M, Papotti M, Dogliotti L, Berruti A. Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen. Ann Oncol 2009; 20:2019-20. [PMID: 19770205 DOI: 10.1093/annonc/mdp456] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Brizzi M, Sculli C, Ragni F, Porpiglia F, Tampellini M, Gorzegno G, Priola A, Dogliotti L, Berruti A. Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma. Ann Oncol 2009; 20:389-90. [DOI: 10.1093/annonc/mdn720] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer 2008; 98:1753-8. [PMID: 18506177 PMCID: PMC2410114 DOI: 10.1038/sj.bjc.6604390] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Persistent circadian rhythm of bone turnover in bone metastatic breast cancer suggests greater skeletal retention of bisphosphonates if administered in the night. We assessed differential effects of night vs morning administration of zoledronic acid (ZA) on bone turnover. Forty-four breast cancer patients with bone metastases were randomised to receive intravenous ZA (4 mg) at 1100 or 2300 hours every 28 days for four times. Urinary concentration N-telopeptide of type-I collagen (NTX) and deoxypyridinolines, and serum C-telopeptide of type-I collagen (CTX), bone alkaline phosphatase (ALP), osteocalcin and Parathyroid hormone (PTH) was measured in the morning at baseline and after 4, 7, 14, 28, 56 and 84 days. Urinary ZA concentration was also measured. Zoledronic acid caused significant decreases of NTX and CTX (P<0.001), without any difference in percent changes between night and morning arms. Bone ALP and osteocalcin were also significantly affected by ZA (P=0.001), without any difference between arms. Parathyroid hormone significantly increased in both the arms; PTH increase was lower in the night arm (P=0.001). From the second administration onwards, urinary ZA level was significantly higher in the night arm (P<0.01). Administration of ZA at two opposite phases of the circadian cycle causes similar changes of bone-turnover marker levels, but has differential effects on the level of serum PTH.
Collapse
Affiliation(s)
- D Generali
- Breast Unit, Azienda Ospedaliera Istituti Ospitalieri, Cremona, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Tampellini M, Alabiso I, Ottone A, Miraglia S, Forti L, Bertona E, Sculli CM, Bellini E, Alabiso O, Dogliotti L. Survival of lung surgery patients with pulmonary metastases from colonic neoplasms. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Berruti A, Vana F, Tucci M, Mosca A, Russo L, Gorzegno G, Saini A, Perotti P, Tampellini M, Dogliotti L. Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 2008; 12:94-9. [DOI: 10.1038/pcan.2008.10] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
38
|
Dovio A, Generali D, Tampellini M, Berruti A, Tedoldi S, Torta M, Bonardi S, Tucci M, Allevi G, Aguggini S, Bottini A, Dogliotti L, Angeli A. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis. Osteoporos Int 2008; 19:113-7. [PMID: 17703272 DOI: 10.1007/s00198-007-0423-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2007] [Accepted: 06/15/2007] [Indexed: 10/22/2022]
Abstract
UNLABELLED The variability of serum osteoprotegerin (OPG) and soluble RANKL (sRANKL) along the 24-h cycle was assessed in 20 healthy women. No rhythmic variations of serum OPG, sRANKL or sRANKL/OPG ratio were detected as a group phenomenon. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL. INTRODUCTION Physiological bone turnover shows diurnal variations. The aim of the study was to assess variability of OPG and sRANKL serum levels along the 24-h cycle. METHODS Blood was collected from 20 healthy women (median age 31 years, range 25-65 years) at 4-h intervals between 08:00 and 24:00 and at 2-h intervals between 24:00 and 08:00. Serum albumin, cortisol, osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX), OPG and total sRANKL were measured. Temporal variations were assessed by the COSINOR model. RESULTS Circadian rhythms of cortisol and albumin documented a normal synchronization within the circadian structure. Serum OC and CTX showed rhythmic variations, peaking at night-time. Rhythmic variations of serum OPG, sRANKL and sRANKL/OPG ratio were not detected as a group phenomenon. On an individual basis, rhythmic changes were detected in ten patients for OPG and eight patients for sRANKL, with very small amplitudes and heterogeneous acrophases. CONCLUSIONS The absence of consistent rhythmic variations of circulating OPG and sRANKL levels may reflect the absence of rhythmic variations of their expression in the bone microenvironment. Were this the case, the nocturnal rise of bone resorption should be accounted for by different, not RANKL/OPG-mediated factors. Since circulating OPG and sRANKL may derive from sources other than bone, rhythmicity could be masked by non-rhythmic or non-synchronized rhythmic expression in these sources. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL.
Collapse
Affiliation(s)
- A Dovio
- Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Bottini A, Generali D, Berruti A, Tampellini M, Torta M, Tedoldi S, Bonardi S, Tucci M, Gorzegno G, Dogliotti L. Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.677] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
677 Background: Z is an effective bisphosphonate in preventing skeletal related events (SREs) in bone metastatic patients. Decrease in bone resorption markers during Z therapy is a potential surrogate of drug efficacy. Bone resorption markers maintain a circadian rhythmicity in metastatic BC patients (Generali et al ASCO 2005), suggesting that Z may be more active if administered in a chronomodulated way. Raised PTH after Z could impair the drug efficacy (Berruti et al ASCO 2006). Methods: Forty-four BC patients with bone metastases were randomised to receive Z, 4 mg i.v. at 11.00 p.m or 11 a.m every 28 days for 4 times. Serum cross laps (CTX), urinary n-telopeptide (NTX) and serum parathyroid hormone (PTH) levels were measured at baseline and after 4, 7, 14, 28, 56 and 84 days, respectively. Results: Z administration in the night resulted in a greater decrease of either serum CTX or urinary NTX and lower increase in serum PTH ( Table ) than morning administration. Conclusions: Z administration in the night might be more efficacious than morning administration. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Bottini
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - D. Generali
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - A. Berruti
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - M. Tampellini
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - M. Torta
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - S. Tedoldi
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - S. Bonardi
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - M. Tucci
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - G. Gorzegno
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| | - L. Dogliotti
- Breast Care Unit, Cremona, Italy; Università di Torino, Orbassano, Italy
| |
Collapse
|
40
|
Berruti A, Dogliotti L, Tampellini M, Lipton A, Hirsh V, Saad F, Liati P, Shirina N, Cook R, Hei YL. Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8610] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8610 Background: Z prevents skeletal-related events (SREs) in pts with bone metastases or multiple myeloma. However, secondary hyperparathyroidism and increased PTH may stimulate osteoclast activity and tumor growth, thus potentially limiting the efficacy of Z. Methods: Serum PTH was assessed at baseline and every 3 months in 1,068 pts enrolled in 3 randomized trials: 547 received Z, and 521 received placebo or pamidronate. Results: 213 (20%) pts had elevated PTH at baseline, and 105 of 547 (19%) pts had elevated PTH during Z treatment. In patients with normal baseline PTH, Z significantly reduced the incidence of SREs and delayed time to first SRE compared with control, whereas the risk of SREs was not reduced in patients with elevated baseline PTH. In prostate cancer patients, Z significantly decreased the risk of death compared with placebo in pts with normal baseline PTH (relative risk [RR] = 0.72; 95% confidence interval [CI]: 0.55, 0.94; P = .015). No survival advantage was observed in this subpopulation among pts with lung cancer or other solid tumors. In the small subset of pts with elevated PTH during Z treatment, there was an increased risk of death (for breast cancer pts, RR = 1.68 [95% CI: 1.10, 2.56]; P = .016; for prostate cancer pts, RR = 2.92 [95% CI: 1.83, 4.67]; P < .001). Additionally, elevated PTH during Z treatment in prostate cancer pts also significantly correlated with an increased risk of bone lesion progression (RR = 1.54 [95% CI: 1.09, 2.17]; P = .015). Elevated PTH during treatment did not affect the incidence or time to onset of SREs. Among pts with lung cancer or other solid tumors, elevated PTH during Z treatment did not provide any predictive or prognostic information. Conclusions: PTH levels either at baseline or during Z treatment appear to correlate with disease progression and the clinical benefit of Z in pts with bone metastases from certain types of cancer. This retrospective analysis suggests the importance of PTH status in patients undergoing Z treatment. Normalization of PTH levels may increase the benefit of Z. [Table: see text]
Collapse
Affiliation(s)
- A. Berruti
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - L. Dogliotti
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - M. Tampellini
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - A. Lipton
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - V. Hirsh
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - F. Saad
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - P. Liati
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - N. Shirina
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - R. Cook
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| | - Y. L. Hei
- Oncologia Medica, Orbassano Torino, Italy; Universita degli Studi di Torino, Torino, Italy; Milton S. Hershey Medical Center, Hershey, PA; McGill University Health Centre, Montreal, PQ, Canada; Centre Hospitalier de l’Université de Montréal, Montréal, PQ, Canada; Novartis Oncology, East Hanover, NJ; University of Waterloo, Waterloo, PQ, Canada
| |
Collapse
|
41
|
Tampellini M, Longo M, Cappia S, Bacillo E, Brizzi M, Bitossi R, Sculli CM, Alabiso I, Dogliotti L, Papotti M. TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13505 Background: Autocrine TGFa in CRC cells regulates cell adhesion via p70S6K phosphorylation in in vitro studies. The aim was to evaluate whether TGFa expression might be correlated with a higher metastatic behavior in vivo. Methods: 101 primitive CRC tumor samples with paraffin blocks available were retrospectively collected. All the specimens were immunohistochemically evaluated for EGFR clone 2–18C9 (Dako), and TGFa clone 213–4 (Calciochem) expression. A score of 0 to 3 was assigned according to staining intensity and extension. EGFR was also evaluated in randomly selected specimens with clone 111.6 (Neomarks) in 81 cases and clone 31G7 (Zymed) in 28 cases. Selected samples were stained for downstream signalling molecules STAT, p-akt, p-MAP kinase, mTor, p-mTor and p70S6K. Patients were divided into 2 groups according to tumor stage at diagnosis: group A stage II-III (51 pts); group B stage IV (50 pts). Results: EGFR clone 2–18C9 reacted in 68/101 (67.3%) cases. Positivity rates and correlation coefficients were: clone 111.6 42/81 (51.9%), r=0.54 (p<0.01); clone 31G7 20/28 (71.4%), r=0.76 (p<0.0001). TGFa was expressed in 79/101 (78.2%) cases. EGFR and TGFa diffuse staining (score 2, 3) was recorded in 14/51 (27.5%) and 18/51 (35.3%) patients in group A, and 26/50 (52.0%) and 27/50 (54.0%) in group B (p=0.01 and p=0.06). EGFR and TGFa coexpression was evident in 23/51 (45.1%) in group A and in 34/50 (68.0%) in group B (p=0.02). No difference in downstream signaling molecule expression was evident between the 2 groups. A positive correlation trend was recorded for p70S6K which was expressed in 8/20 (40%) and in 8/12 (66.7%) samples of group A and B (p=0.15). Conclusions: EGFR, TGFa and p70S6K expression was more common in patients with advanced stage at diagnosis confirming in vitro data. EGFR scores obtained with commercial antibodies from Zymed and Dako had a significant correlation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Tampellini
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - M. Longo
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - S. Cappia
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - E. Bacillo
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - M. Brizzi
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - R. Bitossi
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - C. M. Sculli
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - I. Alabiso
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - L. Dogliotti
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| | - M. Papotti
- Oncologia Medica Aso San Luigi, Torino, Italy; Anatomia Patologica ASO San Luigi, Torino, Italy
| |
Collapse
|
42
|
Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi MP, Sculli CM, Berruti A, Gorzegno G, Magnino A, Sperti E, Miraglia S, Forti L, Alabiso O, Aglietta M, Harris A, Dogliotti L. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br J Cancer 2006; 95:13-20. [PMID: 16773070 PMCID: PMC2360490 DOI: 10.1038/sj.bjc.6603204] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-based first-line chemotherapy in advanced colorectal cancer patients. Data from 631 patients were collected from three different institutions. Globally, overall response rate was 35.8% (226 out of 631). Factors influencing response rate were 5FU dose intensity (high: 43.1%, low: 34.0%, P = 0.03); oxaliplatin (yes: 45.8%, no: 22.9%, P < 0.0001), performance status (PS 0: 46.1%, 1: 28.8%, 2: 26.7%, P < 0.0001), and haemoglobin levels (> or = 12 g dl(-1): 40.4%, < 12 g dl(-1): 29.2%, P = 0.004). In subgroup analysis significant differences in response rate between anaemic and nonanaemic patients were recorded in those patients treated with infusional chemotherapies (45.7 vs 25.5%, P < 0.0001), with high 5FU dose intensity (50.3 vs 32.7%, P = 0.005), with PS = 0 (49.8 vs 37.9%, P = 0.03), and with liver metastases (44.8 vs 33.8%, P = 0.002), whereas no difference was evident in those subjects treated with bolus schedules or according to gender. Anaemia was a strong predictor for activity of first-line 5FU-based chemotherapy especially in those groups that showed the best responses, for example high performance status, infusionally treated, higher 5FU dose and those with liver secondaries. Patients with higher haemoglobin levels recorded a greater response rate and a longer time to progression and survival than anaemic subjects. Prospective evaluation of role of correcting anaemia on response to therapy is justified by these results.
Collapse
Affiliation(s)
- M Tampellini
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - A Saini
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - I Alabiso
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - R Bitossi
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - M P Brizzi
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - C M Sculli
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - A Berruti
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - G Gorzegno
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
| | - A Magnino
- Department of Medical Oncology, University of Torino, IRCC Candiolo, Italy
| | - E Sperti
- Department of Medical Oncology, University of Torino, IRCC Candiolo, Italy
| | - S Miraglia
- Department of Medical Oncology, University of Novara, Novara, Italy
| | - L Forti
- Department of Medical Oncology, University of Novara, Novara, Italy
| | - O Alabiso
- Department of Medical Oncology, University of Novara, Novara, Italy
| | - M Aglietta
- Department of Medical Oncology, University of Torino, IRCC Candiolo, Italy
| | - A Harris
- Department of Medical Oncology, University of Oxford, Oxford, UK
| | - L Dogliotti
- Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy
- E-mail:
| |
Collapse
|
43
|
Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C, Vana F, Lamanna G, Tampellini M, Porpiglia F, Angeli A, Scarpa RM, Dogliotti L. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 2005; 93:633-8. [PMID: 16222309 PMCID: PMC2361623 DOI: 10.1038/sj.bjc.6602767] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Factors predictive of skeletal-related events (SREs) in bone metastatic prostate cancer patients with hormone-refractory disease were investigated. We evaluated the frequency of SREs in 200 hormone-refractory patients consecutively observed at our Institution and followed until death or the last follow-up. Baseline parameters were evaluated in univariate and multivariate analysis as potential predictive factors of SREs. Skeletal-related events were observed in 86 patients (43.0%), 10 of which (5.0%) occurred before the onset of hormone-refractory disease. In univariate analysis, patient performance status (P=0.002), disease extent (DE) in bone (P=0.0001), bone pain (P=0.0001), serum alkaline phosphatase (P=0.0001) and urinary N-telopeptide of type one collagen (P=0.0001) directly correlated with a greater risk to develop SREs, whereas Gleason score at diagnosis, serum PSA, Hb, serum albumin, serum calcium, types of bone lesions and duration of androgen deprivation therapy did not. Both DE in bone (hazard ratio (HR): 1.16, 95% confidence interval (CI): 1.07-1.25, P=0.000) and pain score (HR: 1.13, 95% CI: 1.06-1.20, P=0.000) were independent variables predicting for the onset of SREs in multivariate analysis. In patients with heavy tumour load in bone and great bone pain, the percentage of SREs was almost twice as high as (26 vs 52%, P<0.02) and occurred significantly earlier (P=0.000) than SREs in patients with limited DE in bone and low pain. Bone pain and DE in bone independently predict the occurrence of SREs in bone metastatic prostate cancer patients with hormone-refractory disease. These findings could help physicians in tailoring the skeletal follow-up most appropriate to individual patients and may prove useful for stratifying patients enrolled in bisphosphonate clinical trials.
Collapse
Affiliation(s)
- A Berruti
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - M Tucci
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - A Mosca
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - R Tarabuzzi
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - G Gorzegno
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - C Terrone
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - F Vana
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - G Lamanna
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - M Tampellini
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - F Porpiglia
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - A Angeli
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - R M Scarpa
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | - L Dogliotti
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy
- Dipartimento di Scienze Cliniche e Biologiche Università degli Studi di Torino, Prostate Cancer Unit, Oncologia Medica, Urologia, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy. E-mail:
| |
Collapse
|
44
|
Generali DG, Tedoldi S, Tampellini M, Berruti A, Torta M, Bonardi S, Bottini A, Tucci M, Milani M, Angeli A, Dogliotti L. Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.737] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. G. Generali
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - S. Tedoldi
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - M. Tampellini
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - A. Berruti
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - M. Torta
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - S. Bonardi
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - A. Bottini
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - M. Tucci
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - M. Milani
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - A. Angeli
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| | - L. Dogliotti
- Instituti Ospitalieri Di Cremona, Cremona, Italy; Breast Cancer Unit, Cremona, Italy; San Luigi Hosp, Orbassano, Turin, Italy; Az Istituti Ospitalieri di Cremona, Cremona, Italy
| |
Collapse
|
45
|
Tucci M, Berruti A, Mosca A, Vana F, La Manna G, Russo L, Poggio M, Bitossi R, Gorzegno G, Tampellini M, Saini A. Predictive factors for skeletal complications in prostate cancer patients with hormone refractory disease. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - F. Vana
- ASO S. Luigi, Orbassano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 2005; 12:383-92. [PMID: 15947110 DOI: 10.1677/erc.1.00945] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This study was designed to address whether simultaneous primary chemo-hormonal therapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2-4, N0-1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus tamoxifen (EPI-TAM). Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI-TAM arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)-negative (ER-) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI and EPI-TAM treatments resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI-TAM arm was greater than in the EPI arm, leading to a lower Ki67 expression at post-operative residual histology (P=0.0041). The addition of tamoxifen to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ER- status were both associated with a greater chance of obtaining a pathological complete response at residual histology.
Collapse
Affiliation(s)
- A Bottini
- Breast Unit and Anatomia Patologica Azienda Ospedaliera Istituti Ospitalieri, Cremona, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Forti L, Miraglia S, Bertona E, Rossi V, Rondonotti D, Tampellini M, Porcile G, Alabiso O. Prognostic factors in advanced colorectal carcinoma: A multifactorial analysis. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Forti
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - S. Miraglia
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - E. Bertona
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - V. Rossi
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - D. Rondonotti
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - M. Tampellini
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - G. Porcile
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| | - O. Alabiso
- Osp Maggiore della Carità, Novara, Italy; Osp San Luigi Gonzaga, Orbassano (Torino), Italy; Osp San Lazzaro, Alba (Cuneo), Italy
| |
Collapse
|
48
|
Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi MP, Berruti A, Gorzegno G, Miraglia S, Alabiso O, Dogliotti L. The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Tampellini
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - A. Saini
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - I. Alabiso
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - R. Bitossi
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - M. P. Brizzi
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - A. Berruti
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - G. Gorzegno
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - S. Miraglia
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - O. Alabiso
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| | - L. Dogliotti
- University of Turin, Orbassano, Torino, Italy; University of Novara, Novara, Italy
| |
Collapse
|
49
|
Tucci M, Berruti A, Mosca A, La Manna G, Vana F, Terrone C, Tampellini M, Tarabuzzi R, Gorzegno G, Dogliotti L. The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Tucci
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - A. Berruti
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - A. Mosca
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - G. La Manna
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - F. Vana
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - C. Terrone
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - M. Tampellini
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - R. Tarabuzzi
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - G. Gorzegno
- University of Torino at San Luigi Hospital, Orbassano, Italy
| | - L. Dogliotti
- University of Torino at San Luigi Hospital, Orbassano, Italy
| |
Collapse
|
50
|
Berruti A, Saini A, Gorzegno G, Tampellini M, Borasio P, Dogliotti L. Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy. Ann Oncol 2003; 14:1589-90. [PMID: 14504064 DOI: 10.1093/annonc/mdg420] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|